España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
AstraZeneca
AZN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$71.24
At close: Jan 30, 6:51 PM EDT
$70.70
-0.54
-0.76%
After Hours: 6:51 PM EDT
Get Report
Comment
Q4 2024 Earnings in 6 days from now on Thu Feb 6th, before the market open
Conference call scheduled in 6 days at 6:00 AM
Click to view the webcast
AstraZeneca (AZN) Forecast
News
Earnings
AstraZeneca (AZN) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for AstraZeneca (NASDAQ:AZN) Stock
AstraZeneca Stock (NASDAQ: AZN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, January 31, 2025
Reported Earlier, Daiichi Sankyo And AstraZen...
Benzinga Newsdesk
Wednesday, January 29, 2025
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Anthony Noto
Tuesday, January 28, 2025
"RFK Jr. Says He's Not Anti-Vaccine, Sees Cri...
Benzinga Newsdesk
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
Vandana Singh
Monday, January 27, 2025
AstraZeneca And Daiichi Sankyo's ENHERTU Appr...
Benzinga Newsdesk
Friday, January 24, 2025
AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth
Vandana Singh
Thursday, January 23, 2025
Astrazeneca Announces A $570M Investment In C...
Benzinga Newsdesk
Wednesday, January 22, 2025
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Vandana Singh
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Vandana Singh
Tuesday, January 21, 2025
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
Vandana Singh
Reported Friday, FDA Approves Daiichi Sankyo ...
Benzinga Newsdesk
Friday, January 17, 2025
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline
Vandana Singh
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
Vandana Singh
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma
Vandana Singh
'Ozempic Is In The Next Round Of Medicare Dru...
Benzinga Newsdesk
AstraZeneca's CALQUENCE In Combination With B...
Benzinga Newsdesk
Monday, January 13, 2025
FDA Grants Priority Review to Daiichi Sankyo ...
Benzinga Newsdesk
Tuesday, January 07, 2025
Asher Bio Announces Clinical Supply Agreement...
Benzinga Newsdesk
Thursday, January 02, 2025
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Vandana Singh
Reported Wednesday, HUTCHMED And AstraZeneca'...
Benzinga Newsdesk
Tuesday, December 24, 2024
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
Nabaparna Bhattacharya
Achilles Therapeutics Sells TRACERx And MAP A...
Benzinga Newsdesk
Wednesday, December 18, 2024
Alexion, AstraZeneca Rare Disease Announces A...
Benzinga Newsdesk
Tuesday, December 17, 2024
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
Vandana Singh
Friday, December 13, 2024
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Vandana Singh
"Weight-Loss Drug Craze Appears To Be Curbing...
Benzinga Newsdesk
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
Vandana Singh
Thursday, December 12, 2024
Tracer Biotechnologies Announces Multi-Year P...
Benzinga Newsdesk
Wednesday, December 11, 2024
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
Vandana Singh
Lynparza Shows Significant Survival Benefit I...
Benzinga Newsdesk
Monday, December 09, 2024
Datopotamab Deruxtecan Receives FDA Breakthro...
Benzinga Newsdesk
Sunday, December 08, 2024
AstraZeneca Announced Fixed-duration Calquenc...
Benzinga Newsdesk
Friday, December 06, 2024
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Vandana Singh
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
Vandana Singh
The FDA Has Accepted And Granted Priority Rev...
Benzinga Newsdesk
Reported Earlier, Daiichi Sankyo And AstraZen...
Benzinga Newsdesk
Thursday, December 05, 2024
FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer
Vandana Singh
Wednesday, December 04, 2024
FDA Approves Durvalumab For Limited-Stage Sma...
Benzinga Newsdesk
Tuesday, December 03, 2024
'ADA Advises Against Using Compounded GLP-1 R...
Benzinga Newsdesk
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
Avi Kapoor
Monday, November 25, 2024
AstraZeneca's Truqap Demonstrates Progress in...
Benzinga Newsdesk
Thursday, November 21, 2024
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
Vandana Singh
Wednesday, November 20, 2024
U.S. CDC Says Flu, Covid-19, RSV Illnesses Ar...
Benzinga Newsdesk
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Avi Kapoor
UBS Upgrades AstraZeneca to Neutral
Benzinga Newsdesk
Monday, November 18, 2024
GRAIL Announces The First Patient Has Been Te...
Benzinga Newsdesk
AstraZeneca's Tagrisso (Osimertinib) Has Been...
Benzinga Newsdesk
Friday, November 15, 2024
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vandana Singh
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
Avi Kapoor
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
Pooja Rajkumari
Show More